drugset / Trial / NCT02891837

L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects

NCT02891837

Phase 3 Completed 189 enrolled Asklepion Pharmaceuticals, LLC
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to determine whether L-citrulline is effective and safe in the prevention of clinical sequelae of Acute Lung Injury in pediatric subjects undergoing surgery for congenital heart defects.

Timeline

Start
2016-08
Primary completion
2019-06
Completion
2019-07

Drugs

EvaluationDrugModalityDoseRoute
Subject L-citrulline Other / unclassified 9 mg/kg Intravenous

Indications